← Back to search
CREATIVE TESTING SOLUTIONS
TEMPE, AZ, 85282
Unclaimed
Prime contracting experience
12 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Defense Department of the Army | INFECTIOUS DISEASE TESTING FOR THE ARMED SERVICES BLOOD DONATION PROGRAM AT FORT LEONARD WOOD MISSOURI. | — | $686,775 | Jul 8, 2026 | Oct 1, 2025 – Sep 30, 2027 |
| Prime | Department of Defense Department of the Army | STANDARD TEST PANEL | — | $3,339,004 | Jun 18, 2026 | Oct 1, 2023 – Sep 30, 2026 |
| Prime | Department of Defense Department of the Army | BLOOD DONOR INFECTIOUS DISEASE TESTING, FORT BENNING, GA | — | $481,638 | May 28, 2026 | Oct 1, 2025 – Sep 30, 2027 |
| Prime | Department of Defense Defense Health Agency | BLOOD DONOR AND TRANSPORT | — | $1,713,904 | Apr 9, 2026 | Mar 10, 2025 – Mar 9, 2027 |
| Prime | Department of Defense Department of the Army | BLOOD DONOR TESTING SERVICES - WILLIAM BEAUMONT ARMY MEDICAL CENTER (WBAMC), FORT BLISS, TEXAS. | — | $503,750 | Aug 28, 2025 | Sep 1, 2025 – Aug 31, 2026 |
| Prime | Department of Defense Department of the Army | BLOOD DONOR TESTING | — | $4,332,565 | Apr 3, 2025 | Oct 1, 2020 – Sep 30, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF CREATIVE TESTING SOLUTIONS:1195431 [18-005705] | HHSN269201700003IUSAspending | $649,777 | Nov 15, 2024 | Feb 28, 2019 – Jan 31, 2020 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF CREATIVE TESTING SOLUTIONS:1195431 [18-005705] | HHSN269201700003IUSAspending | $590,753 | Sep 16, 2024 | Feb 2, 2018 – Jan 31, 2019 |
| Prime | Department of Defense Defense Health Agency | BLOOD DONOR AND TRANSPORT | — | $3,318,419 | Feb 29, 2024 | Mar 1, 2020 – Feb 28, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | CREATIVE TESTING SOLUTIONS:1195431 [17-002555] | HHSN269201700003IUSAspending | $590,355 | Sep 20, 2023 | Feb 1, 2017 – Jan 31, 2018 |
| Prime | Department of Defense Department of the Army | COVID-19 2020 INFECTIOUS DISEASE TESTING | — | $5,646,745 | Jun 16, 2023 | Aug 1, 2020 – Oct 31, 2023 |
| Prime | Department of Defense Department of the Army | IGF::CT::IGF BLOOD TESTING FOR INFECTIOUS DISEASES AND CONFIRMATORY TESTING | — | $3,630,517 | Jan 4, 2022 | Feb 1, 2016 – Oct 31, 2020 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
9 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | CTS WILL PROCURE SAMPLES FOR VITALANT, ARC, ONEBLOOD AND WILL PROCESS SAMPLES FOR NYBC, OF UP TO A TOTAL OF 10,000 UNIQUE DONOR SAMPLES CONSISTING OF 4 PACKED WHOLE BLOOD + 1 PLASMA SAMPLE ALIQUOTS OF 0.5ML EACH BASED ON LISTS OF SAMPLES PROVIDED BY EACH BLOOD CENTER ACCORDING TO QUALIFYING AGE, SEX, ZIP CODE OF RESIDENCE AND FIRST TIME OR REPEAT DONOR STATUS. 11832CTS157 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: AZ Parent award description: TTIMS LRCC REQUIREMENT View parent award on USAspending | — | $111,738 | Feb 12, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THE PURPOSE OF THIS AMENDMENT NO. 1 IS TO INCREASE THE TOTAL AWARD BY $200,000.00, FOR A TOTAL OF $769,088, TO COVER ADDITIONAL WORK BEING PERFORMED UNDER THE CDC REPEAT DONOR COHORT STUDY THROUGH THE PROJECT END DATE OF MAY 11, 2024. 11781CTS165 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541380 Parent award performance state: AZ Parent award description: CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION View parent award on USAspending | — | $200,000 | Mar 19, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | CTS WILL PROCURE SAMPLES FOR VITALANT, ARC, ONEBLOOD AND WILL PROCESS SAMPLES FOR NYBC, OF UP TO A TOTAL OF 10,000 UNIQUE DONOR SAMPLES CONSISTING OF 4 PACKED WHOLE BLOOD + 1 PLASMA SAMPLE ALIQUOTS OF 0.5ML EACH BASED ON LISTS OF SAMPLES PROVIDED BY EACH BLOOD CENTER ACCORDING TO QUALIFYING AGE, SEX, ZIP CODE OF RESIDENCE AND FIRST TIME OR REPEAT DONOR STATUS. 11832CTS157 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: AZ Parent award description: TTIMS LRCC REQUIREMENT View parent award on USAspending | — | $122,780 | Dec 18, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | CTS WILL PROCURE SAMPLES FOR VITALANT, ARC, ONEBLOOD AND WILL PROCESS SAMPLES FOR NYBC, OF UP TO A TOTAL OF 10,000 UNIQUE DONOR SAMPLES CONSISTING OF 4 PACKED WHOLE BLOOD + 1 PLASMA SAMPLE ALIQUOTS OF 0.5ML EACH BASED ON LISTS OF SAMPLES PROVIDED BY EACH BLOOD CENTER ACCORDING TO QUALIFYING AGE, SEX, ZIP CODE OF RESIDENCE AND FIRST TIME OR REPEAT DONOR STATUS. 11832CTS157 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: AZ Parent award description: TTIMS LRCC REQUIREMENT View parent award on USAspending | — | $122,780 | Dec 18, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | CTS WILL PROCURE SAMPLES FOR VITALANT, ARC, ONEBLOOD AND WILL PROCESS SAMPLES FOR NYBC, OF UP TO A TOTAL OF 10,000 UNIQUE DONOR SAMPLES CONSISTING OF 4 PACKED WHOLE BLOOD + 1 PLASMA SAMPLE ALIQUOTS OF 0.5ML EACH BASED ON LISTS OF SAMPLES PROVIDED BY EACH BLOOD CENTER ACCORDING TO QUALIFYING AGE, SEX, ZIP CODE OF RESIDENCE AND FIRST TIME OR REPEAT DONOR STATUS. 11832CTS157 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: AZ Parent award description: TTIMS LRCC REQUIREMENT View parent award on USAspending | — | $82,448 | Jul 21, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THE TTIMS LRCC PROJECT PURPOSE IS TO SERVE AS THE BIOSTATISTICAL AND ANALYTICAL CENTER FOR SPECIFIC ANALYSES RELEVANT TO THE EVALUATION AND MONITORING OF HIV (INCIDENT AND PREVALENT INFECTIONS), HCV (INCIDENT) AND HBV (INCIDENT), AND SYPHILIS POSITIVE BLOOD DONORS. SPECIFICALLY, THE PRIMARY OBJECTIVES OF THIS CONTRACT ARE TO: ÃƑ€Š ¢ EVALUATE AND MONITOR RISK FACTOR CHARACTERISTICS OF DONATIONS CONFIRMED POSITIVE FOR TTIS AND COMPARISON UNINFECTED (CONTROL) DONORS. ÃƑ€Š ¢ COMPARE/ANALYZE RISK FACTOR DATA TO THAT OBTAINED IN THE EARLIER TTIMS STUDY PERIOD AND THE REDS-II TTVI MARKER PREVALENCE AND RISK FACTOR STUDY. ÃƑ€Š ¢ INTEGRATE RISK FACTOR DATA AND DISEASE MARKER SURVEILLANCE INFORMATION ACROSS DIFFERENT BLOOD COLLECTION ORGANIZATIONS. ÃƑ€Š ¢ MONITOR ARV AND PREP/PEP USE IN US ALLOGENEIC BLOOD DONOR POPULATION BASED ON TESTING OF BOTH HIV-POSITIVE AND INFECTION NEGATIVE DONATIONS FOR THE PRESENCE OF ARV DRUGS. ÃƑ€Š ¢ EXPLORE THE CHARACTERISTICS OF BLOOD DONORS WHO USE ARV/PREP/PEP TO BETTER UNDERSTAND THEIR RISKS, KNOWLEDGE, AND MOTIVATIONS FOR DONATING WHILE USING THESE THERAPIES. ÃƑ€Š ¢ EVALUATE WELL-CHARACTERIZED US BLOOD DONOR SAMPLES FROM TTIMS AND OTHER SOURCES FOR THE REFINEMENT OF EXISTING ANALYTICAL METHODS SUCH AS THE SEDIA LAG AVIDITY ASSAY TO DERIVE ESTIMATES OF RECENT INFECTION WITH HIV WITH A GOAL OF RAPIDLY OBTAINING MORE ACCURATE AND TIMELY RESULTS. ÃƑ€Š ¢ PROVIDE LOGISTICAL SUPPORT FOR THE TTIMS PROJECT AND FOR THE COMMITTEE/SUBCOMMITTEE MEETINGS, CONFERENCES, AND DONATION(S) TRANSFER/SHIPMENT. IN SUPPORT OF THESE OBJECTIVES, CTS WILL PROVIDE BIOSPECIMENS FOR THE TTIMS REPOSITORY FOR SOME OF THE PARTICIPATING BLOOD CENTERS, PARTICIPATE IN EXISTING SPECIMEN ACQUISITION FOR ADDITIONAL APPROVED PROTOCOLS, AND WILL ACTIVELY COLLABORATE IN THE ANALYSIS, INTERPRETATION, AND REPORTING OF FINDINGS IN TTIMS. DR. PHILLIP WILLIAMSON WILL SERVE AS THE PRINCIPAL INVESTIGATOR (PI) AT CTS. HE WILL OVERSEE ALL ASPECTS OF CTSÃƑ€Š PARTICIPATION IN THE LRCC PORTION OF TTIMS, INCLUDING ACQUISITION OF BIOSPECIMENS AND PROVISION OF DATA RELEVANT TO BE ABLE TO LINK SPECIMENS TO DONOR DEMOGRAPHIC DATA SUPPLIED BY THE PARTICIPATING BLOOD CENTERS. DR. WILLIAMSON OR HIS DESIGNEES WILL ALSO PARTICIPATE IN CALLS AND MEETINGS FOR THE TTIMS PROJECT LIKE THE TTIMS STEERING COMMITTEE. BLOOD CENTER STAFF WILL FORWARD PLASMA BAGS AND/OR PILOT TUBES TO CTS SO THAT CTS CAN CREATE UP TO 5 X 2 ML PLASMA CYROVIALS AND A SINGLE 15 ML PLASMA CRYOVIAL FOR EACH PARTICIPANT AND PREPARE ALIQUOTS FOR SHIPMENT TO THE REPOSITORY AND ADDITIONAL TESTING AT VRI FOR ALL INFECTIONS OF INTEREST AS DEFINED BY THE TTIMS STEERING COMMITTEE. IN COLLABORATION WITH THE LRCC, CTS WILL COORDINATE SAMPLE SHIPMENT WITH DESIGNATED CTS STAFF TO THE TTIMS REPOSITORY HELD IN SAN FRANCISCO. CTS WILL ASSIST TO SOURCE SPECIMENS FOR ARV/PEP/PREP TESTING FROM RESIDUAL SAMPLE VOLUMES FOLLOWING ROUTINE INFECTIOUS DISEASE MARKER TESTING. ADDENDUMS TO THIS SOW WILL BE DEVELOPED AFTER THE RESEARCH PROTOCOLS TO SUPPORT EXPANDED ART/PEP/PREP STUDIES ARE FULLY DEFINED AND APPROVED BY THE TTIMS STEERING COMMITTEE. CTS MAY ALSO CONDUCT ADDITIONAL TESTING AS REQUIRED BY THE TTIMS PROGRAM. AN EXAMPLE OF THIS TESTING IS THE 10-FOLD REPLICATE TESTING TO CONFIRM HIV SEROLOGY-ONLY SAMPLE RESULTS. THIS TESTING WILL BE CHARGED TO THE PRIME AWARD RATHER THAN BUDGETED IN THE CTS SUBCONTRACT. 11832CTS157 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: AZ Parent award description: TTIMS LRCC REQUIREMENT View parent award on USAspending | — | $40,952 | Apr 26, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | CTS WILL PERFORM QUANT IGG TESTING AT 1:400 DILUTIONS ON 54,000 AND TOTAL NUCLEOCAPSID TESTING ON 50,000
SELECTED SAMPLES FROM THE STUDY€„¢S REPEAT DONOR COHORT AT A RATE OF $3.16 PER TEST. IN ADDITION, CTS STAFF, LED BY
DR. MARION LANTERI, WILL CONTRIBUTE TO STUDY EXECUTION INCLUDING DATA ANALYSIS AND MANUSCRIPT DEVELOPMENT PER
BELOW AND PER THEIR ATTACHED BUDGET.
MARION LANTERI WILL DEDICATE 3 MONTHS OR 25% EFFORT TO THIS PROJECT. DR. LANTERI WILL ATTEND WEEKLY PHONE
CALLS AND REGULAR VIRTUAL AND IN PERSON MEETINGS TO PLAN AND COORDINATE ACTIVITIES REQUIRING CTS ENGAGEMENT.
SHE OVERSEES CTS R&D DEPARTMENT AND WILL PRIORITIZE TESTING ACTIVITIES WITHIN CTS R&D DEPARTMENT TO MEET
THE EXPECTED TIMELINES OF STUDY DELIVERABLES RELATED TO SAMPLE TESTING AND RESULTS TURNAROUND. DR. LANTERI WILL
ACTIVELY CONTRIBUTE TO DATA ANALYSES, PUBLIC PRESENTATIONS, AND PUBLICATIONS (ABSTRACT SUBMISSION TO KEY
CONFERENCES AND MANUSCRIPT DEVELOPMENT).
VALERI GREEN WILL DEDICATE 3.2 MONTHS ON THIS PROJECT, INCLUDING 40% EFFORT OVER THE FIRST 4 MONTHS AND 20%
FOR THE FOLLOWING 8 MONTHS. THIS INCLUDES 40% OF HER ACTIVITY DURING THE FIRST 4 MONTHS OF THIS NO COST EXTENSION
PERIOD AS SHE MANAGES THE R&D STAFF INVOLVED IN SAMPLE TESTING ACTIVITIES FOR THIS PROJECT; SHE WILL ORGANIZE THE
WORKFLOW OF SAMPLES AND TESTING AT CTS, ENSURE SAMPLES ARE TESTED IN A TIMELY MANNER, REVIEW RESULTS FOR
ACCURACY, ORGANIZE FOR RESULTS TO BE PROVIDED TO VRI. SHE WILL MAKE SURE REAGENTS ARE ORDERED IN TIME,
INSTRUMENTS ARE PROPERLY MAINTAINED, AND WORKLOAD IS EFFECTIVELY MANAGED. AFTER THE FIRST 4 MONTHS OF MORE
INTENSE TESTING ACTIVITIES, MRS. GREEN€„¢S EFFORT WILL DROP DOWN TO 20% TO ORGANIZE FOR COMPLEMENTARY TESTING AS
NEEDED WHILE CONTRIBUTING TO DATA ANALYSES AND PUBLICATION EFFORTS UNDER THE SUPERVISION OF DR. LANTERI.
SHERRI CYRUS WILL DEDICATE 1.2 MONTHS OR 10% OF HER ACTIVITY TO THIS PROJECT. SHE WILL ATTEND WEEKLY PHONE
CALLS AND REGULAR VIRTUAL MEETINGS THROUGHOUT THE DURATION OF THIS PROJECT. MRS. CYRUS WILL ALSO MANAGE ORDERS,
INVOICES AND PROPER ACCOUNTING FOR THIS PROJECT. SHE WILL SERVE AS BACK-UP FOR MRS. GREEN DURING VACATION AND
SICK TIME AND WILL TAKE OVER CTS R&D STAFF MANAGEMENT AS NEEDED THROUGHOUT THE DURATION OF THE PROJECT.
ONE MEMBER OF THE CTS IT AND BUSINESS INTELLIGENCE TEAM WILL DEDICATE 0.5 MONTH OR 4% EFFORT ON THIS
PROJECT TO HELP MAINTAIN, MODIFY AS NEEDED, AND MANAGE THE COHORT WEB APP ALLOWING FOR CONTINUOUS
GENERATION OF LIST OF SAMPLES NEEDING TESTING, AND RESULTS TO BE RETURNED IN THE FORMAT REQUIRED FOR ONGOING
DATABASE POPULATION. 11781CTS165 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541380 Parent award performance state: AZ Parent award description: CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION View parent award on USAspending | — | $569,088 | Mar 28, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THE TTIMS LRCC PROJECT PURPOSE IS TO SERVE AS THE BIOSTATISTICAL AND ANALYTICAL CENTER FOR SPECIFIC ANALYSES RELEVANT TO THE EVALUATION AND MONITORING OF HIV (INCIDENT AND PREVALENT INFECTIONS), HCV (INCIDENT) AND HBV (INCIDENT), AND SYPHILIS POSITIVE BLOOD DONORS. SPECIFICALLY, THE PRIMARY OBJECTIVES OF THIS CONTRACT ARE TO: ÃƑ€Š ¢ EVALUATE AND MONITOR RISK FACTOR CHARACTERISTICS OF DONATIONS CONFIRMED POSITIVE FOR TTIS AND COMPARISON UNINFECTED (CONTROL) DONORS. ÃƑ€Š ¢ COMPARE/ANALYZE RISK FACTOR DATA TO THAT OBTAINED IN THE EARLIER TTIMS STUDY PERIOD AND THE REDS-II TTVI MARKER PREVALENCE AND RISK FACTOR STUDY. ÃƑ€Š ¢ INTEGRATE RISK FACTOR DATA AND DISEASE MARKER SURVEILLANCE INFORMATION ACROSS DIFFERENT BLOOD COLLECTION ORGANIZATIONS. ÃƑ€Š ¢ MONITOR ARV AND PREP/PEP USE IN US ALLOGENEIC BLOOD DONOR POPULATION BASED ON TESTING OF BOTH HIV-POSITIVE AND INFECTION NEGATIVE DONATIONS FOR THE PRESENCE OF ARV DRUGS. ÃƑ€Š ¢ EXPLORE THE CHARACTERISTICS OF BLOOD DONORS WHO USE ARV/PREP/PEP TO BETTER UNDERSTAND THEIR RISKS, KNOWLEDGE, AND MOTIVATIONS FOR DONATING WHILE USING THESE THERAPIES. ÃƑ€Š ¢ EVALUATE WELL-CHARACTERIZED US BLOOD DONOR SAMPLES FROM TTIMS AND OTHER SOURCES FOR THE REFINEMENT OF EXISTING ANALYTICAL METHODS SUCH AS THE SEDIA LAG AVIDITY ASSAY TO DERIVE ESTIMATES OF RECENT INFECTION WITH HIV WITH A GOAL OF RAPIDLY OBTAINING MORE ACCURATE AND TIMELY RESULTS. ÃƑ€Š ¢ PROVIDE LOGISTICAL SUPPORT FOR THE TTIMS PROJECT AND FOR THE COMMITTEE/SUBCOMMITTEE MEETINGS, CONFERENCES, AND DONATION(S) TRANSFER/SHIPMENT. IN SUPPORT OF THESE OBJECTIVES, CTS WILL PROVIDE BIOSPECIMENS FOR THE TTIMS REPOSITORY FOR SOME OF THE PARTICIPATING BLOOD CENTERS, PARTICIPATE IN EXISTING SPECIMEN ACQUISITION FOR ADDITIONAL APPROVED PROTOCOLS, AND WILL ACTIVELY COLLABORATE IN THE ANALYSIS, INTERPRETATION, AND REPORTING OF FINDINGS IN TTIMS. DR. PHILLIP WILLIAMSON WILL SERVE AS THE PRINCIPAL INVESTIGATOR (PI) AT CTS. HE WILL OVERSEE ALL ASPECTS OF CTSÃƑ€Š PARTICIPATION IN THE LRCC PORTION OF TTIMS, INCLUDING ACQUISITION OF BIOSPECIMENS AND PROVISION OF DATA RELEVANT TO BE ABLE TO LINK SPECIMENS TO DONOR DEMOGRAPHIC DATA SUPPLIED BY THE PARTICIPATING BLOOD CENTERS. DR. WILLIAMSON OR HIS DESIGNEES WILL ALSO PARTICIPATE IN CALLS AND MEETINGS FOR THE TTIMS PROJECT LIKE THE TTIMS STEERING COMMITTEE. BLOOD CENTER STAFF WILL FORWARD PLASMA BAGS AND/OR PILOT TUBES TO CTS SO THAT CTS CAN CREATE UP TO 5 X 2 ML PLASMA CYROVIALS AND A SINGLE 15 ML PLASMA CRYOVIAL FOR EACH PARTICIPANT AND PREPARE ALIQUOTS FOR SHIPMENT TO THE REPOSITORY AND ADDITIONAL TESTING AT VRI FOR ALL INFECTIONS OF INTEREST AS DEFINED BY THE TTIMS STEERING COMMITTEE. IN COLLABORATION WITH THE LRCC, CTS WILL COORDINATE SAMPLE SHIPMENT WITH DESIGNATED CTS STAFF TO THE TTIMS REPOSITORY HELD IN SAN FRANCISCO. CTS WILL ASSIST TO SOURCE SPECIMENS FOR ARV/PEP/PREP TESTING FROM RESIDUAL SAMPLE VOLUMES FOLLOWING ROUTINE INFECTIOUS DISEASE MARKER TESTING. ADDENDUMS TO THIS SOW WILL BE DEVELOPED AFTER THE RESEARCH PROTOCOLS TO SUPPORT EXPANDED ART/PEP/PREP STUDIES ARE FULLY DEFINED AND APPROVED BY THE TTIMS STEERING COMMITTEE. CTS MAY ALSO CONDUCT ADDITIONAL TESTING AS REQUIRED BY THE TTIMS PROGRAM. AN EXAMPLE OF THIS TESTING IS THE 10-FOLD REPLICATE TESTING TO CONFIRM HIV SEROLOGY-ONLY SAMPLE RESULTS. THIS TESTING WILL BE CHARGED TO THE PRIME AWARD RATHER THAN BUDGETED IN THE CTS SUBCONTRACT. 11832CTS157 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: AZ Parent award description: TTIMS LRCC REQUIREMENT View parent award on USAspending | — | $121,554 | Feb 22, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THE TTIMS LRCC PROJECT PURPOSE IS TO SERVE AS THE BIOSTATISTICAL AND ANALYTICAL CENTER FOR SPECIFIC ANALYSES RELEVANT TO THE EVALUATION AND MONITORING OF HIV (INCIDENT AND PREVALENT INFECTIONS), HCV (INCIDENT) AND HBV (INCIDENT), AND SYPHILIS POSITIVE BLOOD DONORS. SPECIFICALLY, THE PRIMARY OBJECTIVES OF THIS CONTRACT ARE TO:
€¢ EVALUATE AND MONITOR RISK FACTOR CHARACTERISTICS OF DONATIONS CONFIRMED POSITIVE FOR TTIS AND COMPARISON UNINFECTED (CONTROL) DONORS.
€¢ COMPARE/ANALYZE RISK FACTOR DATA TO THAT OBTAINED IN THE EARLIER TTIMS STUDY PERIOD AND THE REDS-II TTVI MARKER PREVALENCE AND RISK FACTOR STUDY.
€¢ INTEGRATE RISK FACTOR DATA AND DISEASE MARKER SURVEILLANCE INFORMATION ACROSS DIFFERENT BLOOD COLLECTION ORGANIZATIONS.
€¢ MONITOR ARV AND PREP/PEP USE IN US ALLOGENEIC BLOOD DONOR POPULATION BASED ON TESTING OF BOTH HIV-POSITIVE AND INFECTION NEGATIVE DONATIONS FOR THE PRESENCE OF ARV DRUGS.
€¢ EXPLORE THE CHARACTERISTICS OF BLOOD DONORS WHO USE ARV/PREP/PEP TO BETTER UNDERSTAND THEIR RISKS, KNOWLEDGE, AND MOTIVATIONS FOR DONATING WHILE USING THESE THERAPIES.
€¢ EVALUATE WELL-CHARACTERIZED US BLOOD DONOR SAMPLES FROM TTIMS AND OTHER SOURCES FOR THE REFINEMENT OF EXISTING ANALYTICAL METHODS SUCH AS THE SEDIA LAG AVIDITY ASSAY TO DERIVE ESTIMATES OF RECENT INFECTION WITH HIV WITH A GOAL OF RAPIDLY OBTAINING MORE ACCURATE AND TIMELY RESULTS.
€¢ PROVIDE LOGISTICAL SUPPORT FOR THE TTIMS PROJECT AND FOR THE COMMITTEE/SUBCOMMITTEE MEETINGS, CONFERENCES, AND DONATION(S) TRANSFER/SHIPMENT.
IN SUPPORT OF THESE OBJECTIVES, CTS WILL PROVIDE BIOSPECIMENS FOR THE TTIMS REPOSITORY FOR SOME OF THE PARTICIPATING BLOOD CENTERS, PARTICIPATE IN EXISTING SPECIMEN ACQUISITION FOR ADDITIONAL APPROVED PROTOCOLS, AND WILL ACTIVELY COLLABORATE IN THE ANALYSIS, INTERPRETATION, AND REPORTING OF FINDINGS IN TTIMS.
DR. PHILLIP WILLIAMSON WILL SERVE AS THE PRINCIPAL INVESTIGATOR (PI) AT CTS. HE WILL OVERSEE ALL ASPECTS OF CTS€„¢ PARTICIPATION IN THE LRCC PORTION OF TTIMS, INCLUDING ACQUISITION OF BIOSPECIMENS AND PROVISION OF DATA RELEVANT TO BE ABLE TO LINK SPECIMENS TO DONOR DEMOGRAPHIC DATA SUPPLIED BY THE PARTICIPATING BLOOD CENTERS. DR. WILLIAMSON OR HIS DESIGNEES WILL ALSO PARTICIPATE IN CALLS AND MEETINGS FOR THE TTIMS PROJECT LIKE THE TTIMS STEERING COMMITTEE.
BLOOD CENTER STAFF WILL FORWARD PLASMA BAGS AND/OR PILOT TUBES TO CTS SO THAT CTS CAN CREATE UP TO 5 X 2 ML PLASMA CYROVIALS AND A SINGLE 15 ML PLASMA CRYOVIAL FOR EACH PARTICIPANT AND PREPARE ALIQUOTS FOR SHIPMENT TO THE REPOSITORY AND ADDITIONAL TESTING AT VRI FOR ALL INFECTIONS OF INTEREST AS DEFINED BY THE TTIMS STEERING COMMITTEE. IN COLLABORATION WITH THE LRCC, CTS WILL COORDINATE SAMPLE SHIPMENT WITH DESIGNATED CTS STAFF TO THE TTIMS REPOSITORY HELD IN SAN FRANCISCO.
CTS WILL ASSIST TO SOURCE SPECIMENS FOR ARV/PEP/PREP TESTING FROM RESIDUAL SAMPLE VOLUMES FOLLOWING ROUTINE INFECTIOUS DISEASE MARKER TESTING. ADDENDUMS TO THIS SOW WILL BE DEVELOPED AFTER THE RESEARCH PROTOCOLS TO SUPPORT EXPANDED ART/PEP/PREP STUDIES ARE FULLY DEFINED AND APPROVED BY THE TTIMS STEERING COMMITTEE.
CTS MAY ALSO CONDUCT ADDITIONAL TESTING AS REQUIRED BY THE TTIMS PROGRAM. AN EXAMPLE OF THIS TESTING IS THE 10-FOLD REPLICATE TESTING TO CONFIRM HIV SEROLOGY-ONLY SAMPLE RESULTS. THIS TESTING WILL BE CHARGED TO THE PRIME AWARD RATHER THAN BUDGETED IN THE CTS SUBCONTRACT. 11832CTS157 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541990 Parent award performance state: AZ Parent award description: TTIMS LRCC REQUIREMENT View parent award on USAspending | — | $122,099 | Jan 26, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of DefenseGov-sourced
- Department of Health and Human ServicesGov-sourced